TGFB1 and diabetic kidney disease: While pirfenidone, an antifibrotic agent, increased eGFR in a diabetic patient cohort [205], a placebo-controlled phase II study utilizing a humanized TGF-β1-specific neutralizing monoclonal antibody alongside renin–angiotensin system blockades did not succeed in slowing the progression of DKD in patients [206].